Professor Raffaele Califano svarar på frågor om behandling av ALK-positiv lungcancer

Professor Raffaele Califano, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester UK, svarar på frågorna:

How would you summarize the state-of-the-art of first-line treatment of ALK+ NSCLC patients?
What challenges and limitations are there with the current first-line treatments of ALD+ NSCLC patients?
What are the possible future directions of treatment of ALK+ NSCLS patients?

Plasmaderiverade terapier